Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

The ‘mind-bending’ bionic arm powered by AI

I was born without lower arms and legs, so I’ve been around prosthetics of all shapes and sizes for as long as I can remember.

I’ve actively avoided those designed for upper arms for most of my adult life, so have never used a bionic hand before.

But when I visited a company in California, which is seeking to take the technology to the next level, I was intrigued enough to try one out — and the results were, frankly, mind-bending.

Prosthetic limbs have come a long way since the early days when they were fashioned out of wood, tin and leather.

Modern-day replacement arms and legs are made of silicone and carbon fibre, and increasingly they are bionic, meaning they have various electronically controlled moving parts to make them more useful to the user. (Feb 2024)


BBC Click reporter Paul Carter tries out a high-tech prosthetic promising a ‘full range of human motion’

Scientists Finally “See” Key Protein That Controls Inflammation

Researchers used advanced microscopy to uncover important protein structures. For the first time, two important protein structures in the human body are being visualized, thanks in part to cutting-edge technology at the University of Cincinnati’s Center for Advanced Structural Biology. This break

Autosomal Recessive Cerebellar Ataxia-27 Caused by a Novel Loss-of-Function Variant of Ganglioside-Induced Differentiation Associated Protein 2 in a Spanish Family

Question Are there more effective systemic treatment options for ERBB2-negative metastatic breast cancer and active brain metastases?

Findings In this nonrandomized clinical trial of 47 patients treated with utidelone plus bevacizumab, the central nervous system objective response rate was 42.6% according to the Response Evaluation Criteria in Solid Tumors version 1.1. The safety profile of this treatment approach was manageable.

Meaning These findings suggest that combination therapy with utidelone plus bevacizumab is a potentially viable treatment for patients with ERBB2-negative metastatic breast cancer and active brain metastases.